Beyond LDL: The New Lipid Targets Reshaping Cardiovascular Risk

The intellectual engine behind this shift is a technique called drug-target Mendelian randomization. The logic is elegant: because we inherit our genes at random, people who happen to carry variants that nudge a specific protein up or down spend a lifetime in a kind of natural experiment. If those nudges track with lower rates of heart disease, the protein becomes a credible drug target — one with decades of human safety data already written into population biology. PCSK9 inhibitors were the proof of concept. The same playbook is now pointing at two new addresses on the lipoprotein map.

Lipoprotein(a), or Lp(a), is an LDL-like particle with an extra protein appendage that makes it unusually atherogenic and unusually stubborn. Levels are roughly 80 to 90 percent genetically determined, largely fixed from birth, and largely unmoved by diet, exercise, or statins. For years, clinicians could measure Lp(a), warn patients about it, and then do essentially nothing. A 2025 review in Current Opinion in Lipidology describes how genetic evidence has put Lp(a) inhibitors — a class of RNA-targeting therapies designed to switch off hepatic Lp(a) production — squarely in late-stage development, with the pharmacologic lipid effects closely mirroring what naturally occurring genetic variants predicted.

That recapitulation matters. When a drug's effect on a biomarker tracks the genetic signal, it raises the prior that the downstream cardiovascular benefit will also follow. It is not proof. Phase 3 outcomes trials remain the arbiter, and at the time of writing those readouts are still pending. But the design of the bet is sounder than any cardiology has placed before.

The second target sits further down the lipid cascade. Lipoprotein lipase is the enzyme that clears triglyceride-rich lipoproteins from circulation, and its activity is throttled by a set of inhibitor proteins — ANGPTL3, ANGPTL4, and apoC-III among them. People who inherit loss-of-function variants in those inhibitors run lower triglycerides, lower remnant cholesterol, and, importantly, lower rates of coronary disease over a lifetime. That genetic pattern has motivated a wave of lipoprotein-lipase pathway activators, including antisense and siRNA therapies designed to dial down the brakes on the enzyme.

The same review notes that beyond their lipid effects, robust genetic evidence supports a broader cardiometabolic benefit from this class — a reasonable expectation given that elevated triglyceride-rich remnants are implicated in pancreatitis, fatty liver, and metabolic syndrome as well as atherosclerosis. Again: genetic evidence is suggestive, not conclusive. The outcomes data will need to land.

This is where the language has to slow down. The genetic case for both targets is strong, and the early pharmacology is encouraging. What is not yet in hand is the thing that ultimately matters to patients: large, randomized cardiovascular outcomes trials demonstrating that lowering Lp(a) or activating lipoprotein lipase reduces heart attacks and strokes in real people over real time. Until those trials report, the appropriate posture is interested, not converted.

It is also worth saying what these therapies are not. They are not replacements for LDL lowering, which remains the foundation of prevention with the deepest evidence base. They are candidates for layering on top of LDL therapy in patients whose residual risk is driven by something else — a high Lp(a) inherited from a parent, say, or persistently elevated remnants despite a normal LDL. The promise, as the reviewers frame it, is a more tailored preventive medicine, where treatment maps to a patient's specific lipoprotein-lipid profile rather than a single number on a lab report.

The history of cardiovascular medicine is littered with biomarkers that looked promising in observational data and disappointed in trials — HDL-raising therapies being the most painful recent example. What is different this time is the discipline of the underlying method: the targets here were not chosen because they correlated with disease in a cohort, but because nature has been running the randomized trial in human populations for millennia. That does not guarantee success. It does mean the bets are better designed than they have ever been, and the next few years of outcomes data will tell us whether the era of tailored lipid lowering has truly arrived.